Rockwell Medical Inc
NASDAQ:RMTI

Watchlist Manager
Rockwell Medical Inc Logo
Rockwell Medical Inc
NASDAQ:RMTI
Watchlist
Price: 2.13 USD -4.48%
Market Cap: 68.8m USD
Have any thoughts about
Rockwell Medical Inc?
Write Note

Rockwell Medical Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Rockwell Medical Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Rockwell Medical Inc
NASDAQ:RMTI
Total Equity
$29.1m
CAGR 3-Years
38%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Total Equity
$878.9m
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
1%
ICU Medical Inc
NASDAQ:ICUI
Total Equity
$2B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
15%
Align Technology Inc
NASDAQ:ALGN
Total Equity
$3.9B
CAGR 3-Years
4%
CAGR 5-Years
25%
CAGR 10-Years
18%
Lantheus Holdings Inc
NASDAQ:LNTH
Total Equity
$1.2B
CAGR 3-Years
33%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Total Equity
$1.3B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
12%
No Stocks Found

Rockwell Medical Inc
Glance View

Market Cap
68.8m USD
Industry
Health Care

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 300 full-time employees. The firm is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. The company is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The firm has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

RMTI Intrinsic Value
1.23 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Rockwell Medical Inc's Total Equity?
Total Equity
29.1m USD

Based on the financial report for Sep 30, 2024, Rockwell Medical Inc's Total Equity amounts to 29.1m USD.

What is Rockwell Medical Inc's Total Equity growth rate?
Total Equity CAGR 5Y
4%

Over the last year, the Total Equity growth was 35%. The average annual Total Equity growth rates for Rockwell Medical Inc have been 38% over the past three years , 4% over the past five years .

Back to Top